Analyst Price Targets — DERM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 25, 2025 10:04 am | Brandon Folkes | H.C. Wainwright | $13.00 | $7.40 | TheFly | Journey Medical initiated with a Buy at H.C. Wainwright |
| March 27, 2025 11:32 am | — | Industrial Alliance Securities | $10.50 | $5.92 | TheFly | Journey Medical price target lowered to $10.50 from $11 at Alliance Global Partners |
Latest News for DERM
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer,…
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.18 per share a year ago.
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz.
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DERM.
U.S. House Trading
No House trades found for DERM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.